CAR T-Cell Therapy for Multiple Myeloma – Global Market Insights and Market Forecast to 2030 – ResearchAndMarkets.com – Yahoo Finance

The "CAR T-Cell Therapy for Multiple Myeloma - Market Insights and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Reasons to Buy

Report Highlights

Key Topics Covered:

1. Key Insights

2. Executive Summary

3. CAR T-Cell Therapy Market Overview at a Glance

3.1 Market Share (%) Distribution of CAR T-Cell Therapy for MM in 2030

4. CAR T-Cell Therapy Background and Overview

4.1 Introduction

4.1.1 CARs Generations

4.1.2 Genetic Engineering of T-Cells

4.1.3 How CAR T-Cell Therapy Works

4.2 The promise of CAR T-cell targeting B cell maturation antigen (BCMA) in multiple myeloma

4.3 Current challenges in CAR T

4.3.1 Therapeutic side effects

4.3.2 CAR T-cells lack of success

4.4 CAR T-cell therapy: Route to reimbursement

4.5 Unmet needs

5. CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis

5.1 Key Findings

5.2 Market Size of CAR T-Cell Therapy in 6MM

5.2.1 Market Size of CAR T-Cell Therapy by Therapies

6. Market Outlook

7. Emerging Drug Profiles for Multiple Myeloma

7.1 bb2121: Celgene Corporation

7.1.1 Product Description

7.1.2 Research and Development

7.1.3 Product Development Activities

7.2 JNJ-68284528 (LCAR-B38M): Janssen Research & Development

7.2.1 Product Description

7.2.2 Research and Development

7.2.3 Product Development Activities

7.3 P-BCMA-101: Poseida Therapeutics

7.3.1 Product Description:

7.3.2 Research and Development

7.3.3 Product Development Activities

7.4 CAR-CD44v6: MolMed S.p.A.

7.4.1 Product Description

7.4.2 Research and Development

7.4.3 Product Development Activities

7.5 JCARH125 (Orvacabtagene autoleucel): Celgene Corporation

7.5.1 Product Description

7.5.2 Research and Development

7.5.3 Product Development Activities

7.6 Descartes-08: Cartesian Therapeutics

7.6.1 Product Description

7.6.2 Research and Development

7.7 CT053 : CARsgen Therapeutics)

7.7.1 Product Description

7.7.2 Research and Development

7.7.3 Product Development Activities

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/auj3ij

View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005373/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original here:
CAR T-Cell Therapy for Multiple Myeloma - Global Market Insights and Market Forecast to 2030 - ResearchAndMarkets.com - Yahoo Finance